Department of Preventive Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Division of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Republic of Korea.
Nephrology (Carlton). 2020 Jul;25(7):544-550. doi: 10.1111/nep.13700. Epub 2020 Feb 12.
This study aimed to determine the utility of chronic kidney disease (CKD)-related health states in the Korean general population by using the standard gamble (SG) method.
Seven hypothetical CKD-related health states were developed and revised based on previous publications. Data from 242 individuals from the Korean general population were obtained via computer-assisted personal interviews and used to evaluate the CKD-related health states by using the visual analogue scale (VAS) and SG methods. Mean and median utility values were calculated for each health state. To assess the reliability of the valuation, some samples were retested and evaluated using intraclass correlation coefficients (ICC).
In all health states, the utility weights from SG were higher than those from VAS. The difference in utility values between the two valuation methods ranged from 0.258 to 0.308. The utility value of CKD grade 3 was the highest and that of peritoneal dialysis (PD) was the lowest. The utility weights tended to decrease in accordance with the progression of CKD. CKD grade 3 was assigned a SG utility value of 0.878, whereas PD was assigned 0.507. The SG utility values of predialysis end-stage renal disease, haemodialysis, kidney transplantation (KT), and post-KT recovery states were 0.666, 0.547, 0.748 and 0.827, respectively. The mean ICC (SD) at the individual level was 0.746 (0.281) for the SG scores.
Our results could be used to measure the burden of kidney disease or to evaluate the economic efficiency of CKD-related interventions.
本研究旨在通过使用标准博弈（SG）法，确定慢性肾脏病（CKD）相关健康状况在韩国一般人群中的应用价值。
根据以往的文献，开发并修订了 7 种假设的 CKD 相关健康状况。通过计算机辅助个人访谈，从韩国一般人群中获得了 242 名个体的数据，并使用视觉模拟量表（VAS）和 SG 方法评估 CKD 相关健康状况。计算了每种健康状况的平均和中位数效用值。为了评估估值的可靠性，一些样本通过组内相关系数（ICC）进行了复测和评估。
在所有健康状况中，SG 的效用权重均高于 VAS。两种估值方法之间的效用值差异在 0.258 到 0.308 之间。CKD 3 级的效用值最高，腹膜透析（PD）的效用值最低。随着 CKD 的进展，效用值趋于降低。CKD 3 级的 SG 效用值为 0.878，而 PD 的 SG 效用值为 0.507。透析前终末期肾病、血液透析、肾移植（KT）和 KT 后恢复状态的 SG 效用值分别为 0.666、0.547、0.748 和 0.827。个体水平的平均 ICC（SD）为 0.746（0.281）。
我们的研究结果可用于衡量肾脏疾病的负担，或评估 CKD 相关干预的经济效益。
